Novel intranasal vaccine targeting SARS-CoV-2 receptor binding domain to mucosal microfold cells and adjuvanted with TLR3 agonist Riboxxim™ elicits strong antibody and T-cell responses in mice
SARS-CoV-2 continues to circulate in the human population necessitating regular booster immunization for its long-term control. Ideally, vaccines should ideally not only protect against symptomatic disease, but also prevent transmission via asymptomatic shedding and cover existing and future variant...
Spremljeno u:
Glavni autori: | , , , , , , , , , , , , , |
---|---|
Format: | Članak |
Jezik: | engleski |
Izdano: |
Philipps-Universität Marburg
2023
|
Teme: | |
Online pristup: | PDF cijeli tekst |
Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|
No abstracts were found for this record.